Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  The Oncologist

• Publication date

  2003-06-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1634/THEONCOLOGIST.8-3-232PMID 12773745
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A New Decision Model for Cost-Utility Comparisons of Chemotherapy in Recurrent Metastatic Breast Cancer

  2012cited by this paper
• Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

  2002cited by this paper
• Efficacy and safety of Herceptin® in women with metastatic breast cancer: results from pivotal clinical studies

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Capecitabine: The new standard in metastatic breast cancer failing anthracycline and taxane-containing chemotherapy? Mature results of a large multicenter phase II trial

  2001cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

  2000cited by this paper
• Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?

  2000cited by this paper
• Systematic overview of cost-utility assessments in oncology.

  2000cited by this paper
• Estimates of the lifetime costs of breast cancer treatment in Canada.

  2000cited by this paper
• Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

  1999cited by this paper
• Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.

  1999cited by this paper
• Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy

  1999cited by this paper
• Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients.

  1998cited by this paper
• Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.

  1998cited by this paper
• Treatment of breast cancer.

  1998cited by this paper
• Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.

  1998cited by this paper
• Cost-utility analysis of taxane therapy.

  1997cited by this paper
• Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.

  1996cited by this paper
• Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.

  1995cited by this paper
• Tentative guidelines for using clinical and economic evaluations revisited.

  1993cited by this paper
• Time-preference Studies in the Health Care Context

  1993cited by this paper
• Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes

  1988cited by this paper
• [Treatment of breast cancer].

  1971cited by this paper

• Ginsenoside Rg3 improves cyclophosphamide-induced immunocompetence in Balb/c mice.

  2019cites this paper
• Combination of chemotherapy and photodynamic therapy for cancer treatment with sonoporation effects

  2018cites this paper
• Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer

  2017cites this paper
• Cost-Effectiveness Analysis of Neoadjuvant Chemotherapy with Intensive Dose of Epirubicin and Different Cycles in Patients with Locally Advanced Breast Cancer: 4 Fe 100 c Vs. 6 Fe 100 C

  2013cites this paper
• Cost-Effectiveness Analysis of Neoadjuvant Chemotherapy with Intensive Dose of Epirubicin and Different Cycles in Patients with Locally Advanced Breast Cancer: 4 Fe100c Vs. 6 Fe100 C

  2013cites this paper
• Cost Effectiveness of Cytotoxic and Targeted Therapy for Metastatic Breast Cancer

  2012cites this paper
• Pharmacoeconomic considerations in the treatment of breast cancer

  2010cites this paper
• Cost Comparison of Capecitabine in Patients With Breast Cancer

  2010cites this paper
• Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.

  2009cites this paper
• Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer

  2009cites this paper
• A Cost-effectiveness Analysis of Capecitabine and Folfox for the Adjuvant Treatement of Stage III Colon Cancer: Which is the More Cost-Effective Option in Ontario?

  2009cites this paper
• Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer.

  2009cites this paper
• Cost-effectiveness analysis of docetaxel (Taxotere®) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer

  2009cites this paper
• Feasibility of using administrative claims data for cost-effectiveness analysis of a clinical trial

  2008cites this paper
• Capecitabine and Docetaxel Combination for the Treatment of Breast Cancer

  2008cites this paper
• Cancer Chemotherapy Update - Docetaxel and Capecitabine (DC) Regimen for Solid Tumors

  2007cites this paper
• Cost-effectiveness of intensive adjuvant chemotherapy for high-risk breast cancer: Is tailored and dose-escalated chemotherapy with growth factor support (GFS) more costly and less effective than marrow-supported high-dose chemotherapy – results from a randomized study

  2007cites this paper
• Effects of capecitabine and vinorelbine on cell proliferation, metabolism and COX2 and p16 expression in breast cancer cell lines and solid tumour tissues.

  2007cites this paper
• Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer.

  2006cites this paper
• Economics of Cancer Care

  2006cites this paper
• [Cost-effectiveness analysis of capecitabine in combination with docetaxel in comparison to docetaxel monotherapy in advanced or metastatic breast cancer in France].

  2005cites this paper
• Treatment of advanced breast cancer: the good, the bad and the ugly.

  2005cites this paper
• Costo-efficacia di capecitabina in combinazione con docetaxel versus docetaxel in monoterapia nel trattamento del carcinoma alla mammella metastatico in pazienti pretrattate con antracicline

  2005cites this paper
• Review of cost-effectiveness analyses in hormonal therapies in advanced breast cancer

  2005cites this paper
• Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study.

  2004cites this paper
• Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

  2002cites this paper
• Clinicoeconomics and Outcomes Research

  year unknowncites this paper